These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32801136)

  • 21. Perioperative beta-blockers for preventing surgery-related mortality and morbidity.
    Blessberger H; Kammler J; Domanovits H; Schlager O; Wildner B; Azar D; Schillinger M; Wiesbauer F; Steinwender C
    Cochrane Database Syst Rev; 2014 Sep; (9):CD004476. PubMed ID: 25233038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
    Barrientos-Regala M; Macabeo RA; Ramirez-Ragasa R; Pestaño NS; Punzalan FER; Tumanan-Mendoza B; Castillo RR
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):461-471. PubMed ID: 32675751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perioperative beta-blockers for preventing surgery-related mortality and morbidity.
    Blessberger H; Kammler J; Domanovits H; Schlager O; Wildner B; Azar D; Schillinger M; Wiesbauer F; Steinwender C
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD004476. PubMed ID: 29533470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
    Ju C; Lai RWC; Li KHC; Hung JKF; Lai JCL; Ho J; Liu Y; Tsoi MF; Liu T; Cheung BMY; Wong ICK; Tam LS; Tse G
    Rheumatology (Oxford); 2020 Sep; 59(9):2340-2349. PubMed ID: 31873735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omega-6 fats for the primary and secondary prevention of cardiovascular disease.
    Hooper L; Al-Khudairy L; Abdelhamid AS; Rees K; Brainard JS; Brown TJ; Ajabnoor SM; O'Brien AT; Winstanley LE; Donaldson DH; Song F; Deane KH
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD011094. PubMed ID: 30488422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
    MacDonald TM; Ford I; Nuki G; Mackenzie IS; De Caterina R; Findlay E; Hallas J; Hawkey CJ; Ralston S; Walters M; Webster J; McMurray J; Perez Ruiz F; Jennings CG;
    BMJ Open; 2014 Jul; 4(7):e005354. PubMed ID: 25011991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
    Mackenzie IS; Ford I; Nuki G; Hallas J; Hawkey CJ; Webster J; Ralston SH; Walters M; Robertson M; De Caterina R; Findlay E; Perez-Ruiz F; McMurray JJV; MacDonald TM;
    Lancet; 2020 Nov; 396(10264):1745-1757. PubMed ID: 33181081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interventions for tophi in gout.
    Sriranganathan MK; Vinik O; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010069. PubMed ID: 25330136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis.
    Guan X; Zhang S; Liu J; Wu F; Zhou L; Liu Y; Su N
    Front Pharmacol; 2022; 13():998441. PubMed ID: 36249825
    [No Abstract]   [Full Text] [Related]  

  • 30. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
    Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
    Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allopurinol for Secondary Prevention in Patients with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ye Y; Liao G; Liu T; Hu X; Chen X; Bai L; Peng Y
    J Cardiovasc Dev Dis; 2023 Sep; 10(9):. PubMed ID: 37754808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis.
    Brunström M; Carlberg B
    JAMA Intern Med; 2018 Jan; 178(1):28-36. PubMed ID: 29131895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Febuxostat on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Al-Abdouh A; Khan SU; Barbarawi M; Upadhrasta S; Munira S; Bizanti A; Elias H; Jat A; Zhao D; Michos ED
    Mayo Clin Proc Innov Qual Outcomes; 2020 Aug; 4(4):434-442. PubMed ID: 32793871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.
    Kang EH; Choi HK; Shin A; Lee YJ; Lee EB; Song YW; Kim SC
    Rheumatology (Oxford); 2019 Dec; 58(12):2122-2129. PubMed ID: 31098635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
    Gunawardhana L; Becker MA; Whelton A; Hunt B; Castillo M; Saag K
    Arthritis Res Ther; 2018 May; 20(1):99. PubMed ID: 29848361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implantable defibrillators versus medical therapy for cardiac channelopathies.
    McNamara DA; Goldberger JJ; Berendsen MA; Huffman MD
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD011168. PubMed ID: 26445202
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.